Abaloparatide: 7 agencies, 2023–2025
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused abaloparatide: all 5 decisive outcomes across 5 agencies were positive or positive with restrictions.
The record spans 2.8 years, opening at AWMSG (Wales) on 21 Mar 2023 and running to 15 Dec 2025.
No assessment is on file from HAS (France), PHARMAC (New Zealand) and TLV (Sweden), each among the eight highest-volume agencies here.
The file is active: 7 of 7 records date from 2023 or later.
Against its own class, abaloparatide is an outlier: 100% of its decisive outcomes were positive, where molecules sharing ATC class H05A average 77%.
4 distinct indication wordings are recorded for abaloparatide by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
1 of these 7 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess abaloparatide, on 21 Mar 2023; ZIN (Netherlands) did not open a file until 15 Dec 2025 — a moderate spread of 2.8 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 3 of 7 dated records fall in 2024 alone.
Restriction is doing real work here: 2 of 5 decisive outcomes narrowed abaloparatide to a subgroup rather than accepting or refusing it outright, at NICE (England) and SMC (Scotland).
7 of the 18 agencies in this archive hold a record for abaloparatide.
The full ledger for abaloparatide reads 3 recommended, 2 restricted, 1 no benefit and 1 not assessed.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| SMC (Scotland) | 7 Jul 2025 | Treatment of osteoporosis in postmenopausal women at increased risk of fracture. | accepted (restricted) | source |
| PBAC (Australia) | 2025 | Osteoporosis | Recommended | source |
| G-BA (Germany) | 2 Oct 2024 | Eladynos — benefit assessment §35a | added benefit: not proven | source |
| NICE (England) | 7 Aug 2024 | NICE TA991 | recommended (optimised) | source |
| CIPM (Spain) | 20 Mar 2024 | Indicación terapéutica autorizada: Tratamiento de la osteoporosis en mujeres posmenopáusicas que presentan un aumento de… | financed by the SNS · art. 92 a, c | source |
2 further decisions for abaloparatide, across 2 agencies, are not shown here. They include the most recent record on file, 15 Dec 2025 from ZIN (Netherlands); its outcome is in the subscriber dataset. They link to 2 further source documents.
Related molecules
- teriparatide — same ATC class H05A — Calcium homeostasis
- palopegteriparatide — same ATC class H05A — Calcium homeostasis
- nemolizumab — also decided by ZIN in 2025Q4
- vutrisiran — also decided by ZIN in 2025Q4
- odevixibat — also decided by ZIN in 2025Q4
- ravulizumab — also decided by ZIN in 2025Q4
Coverage: 7 decisions for abaloparatide from 7 agencies, 2023 to 2025. Data to 7 Sep 2026. ATC class H05A — Calcium homeostasis. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.